How to Buy Centessa Pharmaceuticals Stock
Centessa Pharmaceuticals PLC
Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients.
Centessa Pharmaceuticals stock last closed at $12.67, up 4.28% from the previous day, and has increased 26.7% in one year. It has overperformed other stocks in the Biotechnology industry by 1.04 percentage points. Centessa Pharmaceuticals stock is currently +63.48% from its 52-week low of $7.75, and -33.63% from its 52-week high of $19.09.
At the moment, there are 133.18M CNTA shares outstanding. The market value of CNTA is $1.69B. In the past 24 hours, 566,164 CNTA shares were traded.
How to Buy Centessa Pharmaceuticals Stock
Not sure how to invest in Centessa Pharmaceuticals stock? Here's how.
- Figure out where to buy Centessa Pharmaceuticals stock: You need to decide on a stock brokerage, but don't worry - we've researched dozens of online brokerages and apps to help you choose where to buy Centessa Pharmaceuticals stock.
- Open a brokerage account: Sign up for 0% commission trading with the highest-rated brokerage we've identified.
- Put funds into your investment account: Choose your payment method and add your info.
- Analyze Centessa Pharmaceuticals stock: The Centessa Pharmaceuticals ticker symbol is CNTA. Is Centessa Pharmaceuticals stock a good investment? Should you buy shares of CNTA? How do CNTA's underlying business fundamentals look? Do top analysts think Centessa Pharmaceuticals is a good buy? Why has CNTA's stock price moved recently? (Hint: Our stock market research website can help you evaluate if CNTA is a good stock to buy).
- Place your CNTA buy order: Decide if you will purchase CNTA shares at the current market price or use a limit order to purchase CNTA shares at a particular price.
- Keep an eye on your CNTA investment: Create a watchlist to key updates about your new investment in Centessa Pharmaceuticals stock.
Step 1: Figure out where to buy Centessa Pharmaceuticals stock
You will need a brokerage account to access the NASDAQ market and buy CNTA shares.
Our recommended brokerage: eToro
Based on our research, eToro is the best stock brokerage. eToro gives you:
- You can invest in stocks with 0% commissions: Invest without paying trading commissions.
- Buy fractional shares: Even if you don't have the money to buy a full share, you can still invest in the stock.
- Access to global financial markets: From Tech to Utilities, New York to Hong Kong (for US users, only US stocks are available) — you can fill your portfolio with stocks from the globe's leading stock exchanges.
- Social investing: eToro has a community with more than 20 million users around the world. Talk to, learn from, and copy the crypto trades of other investors.
- Security: eToro is a regulated and licensed fintech leader.
- Buy other assets: Such as ETFs and cryptos.
Get $10 towards your purchase of shares by creating an account with eToro now. This offer is only for US users.
Open eToro AccountStep 2: Open a brokerage account
Now that you've selected the best brokerage, you need to fill out some personal information so you can buy CNTA today.
How to Set Up a New Investment Account on eToro
- Click here to get started.eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
- Provide your personal info to open your new brokerage account.
- Send your information by pressing the "Create Account" button. Get started with eToro today
Step 3: Put funds into your investment account
Now that you have created your account on app for stock market, you can securely and quickly fund your account:
Watch the video below for more details depositing funds into your brokerage account.
Step 4: Analyze Centessa Pharmaceuticals stock
After you have identified the best place to buy Centessa Pharmaceuticals stock, it's crucial to evaluate their stock before you invest, so you can wrap your head around the risk and opportunity.
Centessa Pharmaceuticals stock quick numbers
Centessa Pharmaceuticals Due Diligence Score
WallStreetZen was designed to help part-time investors perform more accurate fundamental analysis.
You can see all of the due diligence checks on CNTA's stock page.
How is CNTA stock valued?
You can use a variety of different financial metrics, analyses, models, and charts to gauge CNTA's fair value.
Using relative valuations ratios:
- CNTA could be overvalued based on its P/B ratio of 4.2x, relative to Biotechnology industry P/B ratio of 4.16x
You can do more valuation analysis on CNTA's stock here.
CNTA Financial Summary
Signs that CNTA is financially healthy:
- Total CNTA debt is lower than 5 years ago, relative to shareholder equity.
- CNTA has cash burn of 142089000. It has sufficient cash and short-term investments to cover this for at least one year.
- CNTA has $482.18M in cash and short term investments. This is sufficient to cover its annual cash burn of $142.09M.
- There are more short-term assets than short-term liabilities on the CNTA balance sheet.
- There are more short-term assets than long-term liabilities on the CNTA balance sheet.
Signs that CNTA is not financially healthy:
- CNTA has a relatively high debt to equity ratio of 0.44.
Is CNTA stock a Buy, Hold, or Sell, according to analysts?
Out of 3 Wall Street analysts who monitor CNTA, the consensus analyst rating on CNTA is a Strong Buy
Please note that analyst forecasts are not recommendations, nor are they financial advice.
You can dive deeper into what analysts are projecting on the Centessa Pharmaceuticals stock forecast page.
CNTA Trading Indicators
CNTA Growth Metrics
Last year, CNTA revenue was $0.00. Over the last one years, CNTA's revenue has grown by -100% per year. This was slower than the Biotechnology industry average of 44.4%.
Dig into CNTA's earnings and revenue performance here.
What are CNTA executives and large shareholders up to?
Over the past year, insiders at CNTA have sold more shares than they have bought.
Saurabh Saha, Chief Executive Officer of CNTA, was the latest CNTA insider to sell. They sold $501,475.92 worth of CNTA stock on Apr 22, 2025.
Learn more about who owns CNTA stock here.
Can I get consistent income from CNTA stock?
No, Centessa Pharmaceuticals doesn't provide an income stream by paying out dividends.
Get analysis from other investors
One of the primary reasons eToro is our top-rated brokerage is because of its social trading community.
Click below to find out what other traders have to say.
Step 5: Place your CNTA buy order
You have two main types of orders:
- Market order: A market order is an order to buy or sell a stock at the best available price.
Market orders are usually the best for newer investors. - Limit order: A limit order is an order to buy or sell a security at a specific price (or better).
If you want to make sure you're buying or selling at a specific dollar amount limit, use a limit order.
Hit the Open button and your broker will place the order.
If you want additional assistance investing in stocks on eToro, watch the helpful video below:
Step 6: Keep an eye on your CNTA investment
Now that you own some shares in CNTA, you'll want to keep up with your shares.
Put CNTA on a watchlist to track the most important metrics related to your CNTA stock.
CNTA Feed
How to Buy Stock in Centessa Pharmaceuticals
To reiterate, here are the 6 steps to buy Centessa Pharmaceuticals stock:
- Figure out where to buy Centessa Pharmaceuticals stock
- Open a brokerage account
- Put funds into your investment account
- Analyze Centessa Pharmaceuticals stock
- Place your CNTA buy order
- Keep an eye on your CNTA investment
If you are looking for a place to buy stocks, eToro is our recommended venue.
Get Started with eToro TodayIf you would like to get updates on your new investment in Centessa Pharmaceuticals, click below.
Trending Articles
FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.